For more than 30 years, the 340B Drug Pricing Program has provided financial help to hospitals serving vulnerable communities to manage rising prescription drug costs.

What is the 340B Program? This program, administered by the Health Resources and Services Administration (HRSA), allows 340B hospitals to stretch limited federal resources to reduce the price of outpatient pharmaceuticals for patients and expand health services to the patients and communities they serve. Hospitals use 340B savings to provide, for example, free care for uninsured patients, offer free vaccines, provide services in mental health clinics, and implement medication management and community health programs. According to HRSA, enrolled hospitals and other covered entities can achieve average savings of 25% to 50% in pharmaceutical purchases.

Which organizations are eligible? Several types of hospitals are eligible to participate in the 340B program including critical access hospitals (CAHs), sole community hospitals (SCHs), rural referral centers (RRCs), public and private nonprofit disproportionate share hospitals (DSHs) that serve high numbers of low-income and indigent populations, and free-standing cancer and children’s hospitals. Several types of federal grantee organizations such as community health centers also are eligible to participate in the program.

What are some challenges to the program? Despite rigorous oversight from HRSA and the program’s proven record of expanding access to care for Americans nationwide, critics continue to push to diminish the scope of the program and the benefits it affords eligible providers and their patients.
 

340B Resources

Member Resources

Join the 340B Alliance Banner

The AHA Advocacy Alliance for the 340B program focuses on promoting the value that the 340B program provides to hospitals, patients and communities, as well as preventing attempts to scale back this program. Join the alliance for access to email communications, conference calls and special briefings. Join the Alliance.


Through email communications like alliance emails, action alerts and special messages, the 340B Alliance keeps hospitals informed of the latest news and developments on the program, as well as actions hospital leaders can take to support the program. Learn More

Image of medicine in pharmacy

Latest 340B Content

Headline
The Centers for Medicare & Medicaid Services July 2 issued a proposed rule that would increase Medicare hospital outpatient prospective payment system rates by a net 2.4% in calendar year 2027 compared to 2026.
Advisory
The Centers for Medicare & Medicaid Services (CMS) July 2 issued a proposed rule that would increase Medicare hospital outpatient prospective payment system (PPS) rates by a net 2.4% in calendar year (CY) 2027 compared to CY 2026.
340B Advocacy Alliance Bulletin
The Centers for Medicare & Medicaid Services July 2 issued a proposed rule that would increase Medicare hospital outpatient prospective payment system rates by a net 2.4% in calendar year 2027 compared to CY 2026.
Advisory
The House Ways and Means Committee today voted to advance a bill, H.R. 9504, the Tax-Exempt Hospitals Transparency Act, that would add reporting requirements for nonprofit hospitals’ Schedule H IRS forms.
340B Advocacy Alliance Bulletin
Join the AHA 340B Advocacy Alliance on July 8 at 3 p.m. ET for the latest updates on the 340B Drug Pricing Program and opportunities to engage directly with AHA 340B team members.
340B Advocacy Alliance Bulletin
Senate Health, Education, Labor, and Pensions Committee Chairman Bill Cassidy, M.D., R-La., today released a legislative discussion draft that would make several changes to the 340B Drug Pricing Program.
340B Advocacy Alliance Bulletin
HRSA seeks input on 340B Rebate Model.
340B Advocacy Alliance Bulletin
The AHA today issued a statement denouncing unprecedented actions taken by Eli Lilly to deny 340B Drug Pricing Program discounts to certain 340B hospitals that do not meet its unilateral data requirements.
Press Releases
AHA can confirm that Eli Lilly has taken the extraordinary action of denying 340B discounts. Congress should immediately use its oversight authority and demand HHS take a position on drug companies’ attempts to hijack the 340B program through burdensome claims-data demands.
340B Advocacy Alliance Bulletin
HRSA seeks input on 340B Rebate Model.